Comparative Pharmacology
Head-to-head clinical analysis: DIMETHYL SULFOXIDE versus QUTENZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIMETHYL SULFOXIDE versus QUTENZA.
DIMETHYL SULFOXIDE vs QUTENZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dimethyl sulfoxide (DMSO) is a polar aprotic solvent that penetrates biological membranes, scavenges hydroxyl radicals, and stabilizes lysosomal membranes. It has anti-inflammatory, analgesic, and cryoprotective properties. It enhances cutaneous absorption of other drugs and induces histamine release from mast cells, causing vasodilation and urticaria.
QUTENZA (capsaicin) is a transient receptor potential vanilloid 1 (TRPV1) agonist. It selectively binds to TRPV1 receptors on cutaneous nociceptors, causing initial excitation followed by defunctionalization and reduced sensitivity to pain.
50% solution topically applied every 6 hours; intravenous: 0.5-1 g/kg as a 10-20% solution over 30-60 minutes every 6 hours for 3-5 doses
Topical patch applied to painful area for 60 minutes every 3 months (up to 4 patches per application).
None Documented
None Documented
Terminal half-life: 11-14 hours for DMSO; DMSO2 half-life 60-70 hours, accumulates with repeated dosing. Clinical context: renal impairment prolongs half-life.
6.5 hours (range 5-8 hours) for systemic capsaicin; transient due to rapid metabolism. Clinically, local effects persist beyond systemic clearance.
Renal: 30-50% unchanged; hepatic metabolism to dimethyl sulfone (DMSO2) and dimethyl sulfide (DMS); DMSO2 excreted renally, DMS exhaled; fecal elimination <5%.
Primarily renal; capsaicin and metabolites excreted in urine, with <1% unchanged. Fecal elimination accounts for <5%.
Category C
Category C
Topical Analgesic
Topical Analgesic